1 / 13

INTRODUCTION TO IFPMA AND THEIR ROLE IN GLOBAL HEALTH POLICY

INTRODUCTION TO IFPMA AND THEIR ROLE IN GLOBAL HEALTH POLICY. Dr. Mümün Gencoglu Regulatory Affairs Manager - International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). IFPMA in Brief. MISSION AND VISION. WHO WE ARE. VISION.

chayton
Download Presentation

INTRODUCTION TO IFPMA AND THEIR ROLE IN GLOBAL HEALTH POLICY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. INTRODUCTION TO IFPMA AND THEIR ROLE IN GLOBAL HEALTH POLICY Dr. Mümün Gencoglu Regulatory Affairs Manager - International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

  2. IFPMA in Brief MISSION AND VISION WHO WE ARE VISION IFPMA is the voice for biopharmaceutical innovation and health progress around the world THOUGHT LEADER Share expertise in key fora about innovation, regulatory and health policy issues SOLUTIONS PARTNER Tackle health challenges responsibly and collaboratively, to improve health outcomes To promote policies, dialoguesand initiatives that encouragethe discovery of and access to medicines and vaccines globally MISSION CONVENER Build bridges within and across sectors to advance mutual goals and gain trust

  3. Bridge between the industry and global health stakeholders IFPMA is a strong, assertive voice for the industry’s value proposition, with a portfolio of constructive initiatives, positioning the industry as thought leaders and solutions partners. IFPMA brings insights on political and policy trends, and external stakeholder perspectives to its members.

  4. Interlocutor for intergovernmental organizations Consultative status with the United Nations: Engage with other multilateral organizations:

  5. IFPMA Membership IFPMA is the industry interlocutor globally with ~50 associations and ~40 companies in all 5 continents 50 Europe: 21 Associations Associations In All 5 Continents Asia Pacific: 15 Associations Americas: 11 Associations Middle East & Africa: 3 Associations

  6. Industry membership

  7. IFPMA strategic priorities Promote policies & dialogue to advance sustainable financing and health system reforms, including access & availability of medicines & vaccines worldwide Advance SustainableHealth Systems “Global Health Progress” Build bridges amongst diverse actors to champion solutions for improving public health and patient outcomes Advocate for policies that enable & recognize the value of science and biopharmaceutical innovation Champion Solutions for Global Health Challenges Foster a Sound Biopharmaceutical Innovation Ecosystem Ethics & Business Integrity

  8. Pharmaceutical Innovation: A long and complex process IFPMA (2012) The New Frontiers of Biopharmaceutical Innovation. Geneva: International Federation of Pharmaceutical Manufacturers & Associations, p 9. http://www.ifpma.org/fileadmin/content/Publication/2013/IFPMA_Incremental_Innovation_Feb_2013_Low-Res.pdf

  9. Pharmaceutical industry investment in R&D European Commission (2015) The 2015 EU Industrial R&D Investment Scoreboard; p50. http://iri.jrc.ec.europa.eu/scoreboard15.html

  10. Innovative Medicines: pushing the limits of science with a vibrant pipeline IFPMA (2017), The Pharmaceutical Industry and Global Health: Facts and Figures 2017. PhRMA (2016) Chart Pack Biopharmaceuticals in Perspective. Washington DC: Pharmaceutical Research and Manufacturers of America, p 22.

  11. IFPMA is advocating for better access to advanced therapies Growth Projections for Cell and Gene Therapy Market 1 RegenerativeMedicinesMarket: Global Opportunity Analysis and IndustryForecast, 2015–2022. AlliedMarketResearch: Pune,Maharashtra, India: August 2016; www.alliedmarketresearch.com/regenerative-medicines-market. 2 Chartrain NA, Williams CB, Whittington AR. Engineering Tissues withBioprinting. BioProcess Int. 14(10) 2016: 28–33.

  12. Building Solutions and forming strategic alliances are a key priority for IFPMA Drive alliance-building programs with other industries and key opinion leaders

  13. Learn more and stay connected www.ifpma.org

More Related